In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Original article: Predictors for efficacy of percutaneous mitral valve repair using the MitraClip system: the results of the MitraSwiss registry

Valvular Heart Diseases

Background Percutaneous mitral valve repair (MVR) using the MitraClip system has become a valid
alternative for patients with severe mitral regurgitation (MR) and high operative risk.

Objective To identify clinical and periprocedural factors that may have an impact on clinical outcome.
Design Multi-centre longitudinal cohort study.
Setting Tertiary referral centres.
Patients Here we report on the first 100 consecutive patients treated with percutaneous MVR in Switzerland between March 2009 and April 2011. All of them had moderate–severe (3+) or severe (4+) MR, and 62% had functional MR. 82% of the patients were in New York Heart Association (NYHA) class III/IV, mean left ventricular ejection fraction was 48% and the median European System for Cardiac Operative Risk Evaluation was 16.9%.
Interventions MitraClip implantation performed under echocardiographic and fluoroscopic guidance in general anaesthesia.
Main outcome measures Clinical, echocardiographic and procedural data were prospectively collected.

Results Acute procedural success (APS, defined as successful clip implantation with residual MR grade ≤2+) was achieved in 85% of patients. Overall survival at 6 and 12 months was 89.9% (95% CI 81.8 to 94.6) and 84.6% (95% CI 74.7 to 91.0), respectively. Univariate Cox regression analysis identified APS (p=0.0069) and discharge MR grade (p=0.03) as significant predictors of survival.

Conclusions In our consecutive cohort of patients, APS was achieved in 85%. APS and residual discharge MR grade are important predictors of mid-term survival after percutaneous MVR.

Notes to editor

Heart 2013;99:1034-1040
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.